By Peter A. McCullough, MD, MPH Monkeypox vaccines include ACAM2000 (used for Smallpox, recently FDA approved for Monkeypox), JYNNEOS, and modified vaccinia Ankara. The at-risk population is young men who are at the highest risk of idiopathic and COVID-19 vaccine myocarditis at baseline. ACAM2000 has been reported to have major cardiovascular adverse events such as myocarditis, dilated cardiomyopathy, and heart failure. Whereas JYNNEOS and modified vaccinia Ankara are associated with minor cardiovascular adverse events such as tachycardia, palpitation, electrocardiogram changes such as T wave inversion, and ST elevation in the peer-reviewed literature. The CDC has reported serious myocarditis from the Bavarian Nordic JYNNEOS vaccine requiring hospitalization of young men